Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 Pipeline Review, H1 2018
Summary
Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 pipeline Target constitutes close to 32 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Leukocyte Surface Antigen CD47 Pipeline Review, H1 2018, outlays comprehensive information on the Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 CD47 Cluster of Differentiation 47 or integrin associated protein IAP is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus By similarity.
It acts as a receptor for SIRPA. Interaction with SIRPG mediates cellcell adhesion, enhances superantigendependent Tcellmediated proliferation and costimulates Tcell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 14 and 10 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular and Metabolic Disorders which include indications Solid Tumor, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Lymphoma, Diffuse Large BCell Lymphoma, Multiple Myeloma Kahler Disease, Myelodysplastic Syndrome, NonHodgkin Lymphoma, Relapsed Multiple Myeloma, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, BCell NonHodgkin Lymphoma, Breast Cancer, Cutaneous TCell Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Bladder Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia CLL, Colorectal Cancer, Diabetic Retinopathy, Follicular Lymphoma, Glioblastoma Multiforme GBM, Head And Neck Cancer, Hematological Tumor, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Ischemia Reperfusion Injury, Kidney Transplant Rejection, Leiomyosarcoma, Leukemias, Marginal Zone Bcell Lymphoma, Melanoma, Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Melanoma, Mycosis Fungoides, Myeloproliferative Disorders, NonSmall Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Peripheral TCell Lymphomas PTCL, Sezary Syndrome, SmallCell Lung Cancer and Squamous Cell Carcinoma.
Furthermore, this report also reviews key players involved in Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47
The report reviews Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 targeted therapeutics and enlists all their major and minor projects
The report assesses Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope